{"id":3052,"date":"2018-06-19T01:29:29","date_gmt":"2018-06-19T05:29:29","guid":{"rendered":"https:\/\/theiyafoundation.org\/?p=3052"},"modified":"2020-02-08T15:04:39","modified_gmt":"2020-02-08T20:04:39","slug":"aakp2018meeting","status":"publish","type":"post","link":"https:\/\/theiyafoundation.org\/2018\/06\/19\/aakp2018meeting\/","title":{"rendered":"Feedback on the 2018 American Association of Kidney Patient\u2019s National Patient Meeting"},"content":{"rendered":"

 <\/p>\n

\"AAKP<\/a><\/p>\n

By Iya Bekondo-Granatella, AAKP Field Ambassador and Founder of the Iya Foundation Inc.<\/p>\n

[June 8th<\/sup> \u2013 June 11th<\/sup>] I had the privilege of attending the 43rd<\/sup> Annual National Kidney Patient Meeting hosted by the American Association of Kidney Patients<\/a> (AAKP) in St. Petersburg, Florida. This event is the largest kidney patient education and advocacy meeting held in the U.S. and brings together patients, caregivers, advocates, healthcare providers and researchers alike. As a newly appointed Field Ambassador of the (AAKP), this was my very first patient meeting. To say the least, it was all of sensational. Not only did I get to connect with so many other advocates, most of whom I had only interacted with online; but I also got to learn so much from the different informative and educational sessions.<\/p>\n

Beforehand, potential attendees were given the opportunity to choose topics of interest they would like to sit in on at the various seminars and lunch with expert sessions; a program which I particularly enjoyed as it was more casual, engaging, and highly interactive. The general session presentations were also quite informative and impactful especially to me as a patient, kidney health educator and advocate.<\/p>\n

Fortunately, I was able to attend the general session presentation by Dr. Robert Star, who talked about some of the medical advancements in the pipeline that would improve the care of kidney patients. Of particular interest to me was his mention of precision medicine to develop treatment plans for kidney patients using renal biopsies. The current approach to treatment is a one-size-fits-all approach that can be very successful for some patients but not so much for others. The innovative approach of precision medicine takes into account individual differences in people\u2019s genes, environments, and lifestyles. It gives medical professionals the resources they need to target specific treatments of the illnesses people encounter and helps develop scientific and medical research. According to Dr. Star, a personalized approach to renal biopsy will improve patient diagnosis and ultimately their treatment option plan. I am excited about all that could become of this approach.<\/p>\n

A launch with expert session with Dr. Star further answered a series of my questions on Acute Kidney Injury, while during another lunch with expert session, I had the opportunity of meeting Mr. Joe Karan from the National Kidney Foundation who shared with us some of the different financial resources available to assist kidney failure patients. It was quite informative.<\/p>\n

I also learnt a lot from Dr. Lee\u2019s presentation on our different kidney related lab tests and Mr. James Myers session on using Social Media to raise awareness. A tour of the exhibit hall introduced me to Third Kidney Inc.<\/a> founder Dr. Raymond Keller Jr, DO who is in the process of developing an innovative approach to reducing the amount of time patients get to spend getting treatments on their dialysis machines. According to his idea, by substituting an hour for hour on an alternative therapy such as medical saunas, patients wouldn’t need to sit for the full current average of 4 to 5 hours getting treatment on their dialysis machine. Instead, part of that could be substituted with a sauna therapy according to Dr. Keller.  Although saunas are not yet approved by the Food and Drug Administration for the treatment of advanced stages of neither kidney disease nor any other human disease, this is an idea that does sound promising and may make renal replacement therapies a bit more desirable if approved.<\/p>\n

One of the most important and worthy take home lessons for me was getting informed about the Apolipoprotein L1 (APOL1) gene and its association with disease nephropathy in blacks and African Americans, from Vice President of the AAKP Mr. Richard Knight and seasoned advocate and AAKP Field Ambassador, Ms. Nichole Jefferson. Further research on this gene<\/a> from the National Institute of Health website, taught me the following:<\/p>\n